- Home
- CGTL vs IMAB Comparison
CGTL vs IMAB Comparison
Compare CGTL & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTL
- IMAB
- Stock Information
- Founded
- CGTL 2016
- IMAB 2014
- Country
- CGTL Hong Kong
- IMAB United States
- Employees
- CGTL N/A
- IMAB N/A
- Industry
- CGTL
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- CGTL
- IMAB Health Care
- Exchange
- CGTL NYSE
- IMAB Nasdaq
- Market Cap
- CGTL 70.3M
- IMAB 73.9M
- IPO Year
- CGTL 2024
- IMAB 2020
- Fundamental
- Price
- CGTL $5.62
- IMAB $0.85
- Analyst Decision
- CGTL
- IMAB Strong Buy
- Analyst Count
- CGTL 0
- IMAB 2
- Target Price
- CGTL N/A
- IMAB $5.50
- AVG Volume (30 Days)
- CGTL 628.1K
- IMAB 261.6K
- Earning Date
- CGTL 05-15-2025
- IMAB 04-03-2025
- Dividend Yield
- CGTL N/A
- IMAB N/A
- EPS Growth
- CGTL 35.72
- IMAB N/A
- EPS
- CGTL 0.21
- IMAB N/A
- Revenue
- CGTL $35,611,761.00
- IMAB N/A
- Revenue This Year
- CGTL N/A
- IMAB N/A
- Revenue Next Year
- CGTL N/A
- IMAB N/A
- P/E Ratio
- CGTL $26.25
- IMAB N/A
- Revenue Growth
- CGTL N/A
- IMAB N/A
- 52 Week Low
- CGTL $2.80
- IMAB $0.60
- 52 Week High
- CGTL $10.59
- IMAB $2.00
- Technical
- Relative Strength Index (RSI)
- CGTL N/A
- IMAB 53.01
- Support Level
- CGTL N/A
- IMAB $0.63
- Resistance Level
- CGTL N/A
- IMAB $1.01
- Average True Range (ATR)
- CGTL 0.00
- IMAB 0.10
- MACD
- CGTL 0.00
- IMAB 0.02
- Stochastic Oscillator
- CGTL 0.00
- IMAB 60.39
About CGTL CREATIVE GLOBAL TECHNOLOGY HOLDINGS LIMITED
Creative Global Technology Holdings Ltd conducts its business through its subsidiary, which is a Hong Kong-based company sourcing and reselling recycled consumer electronic devices, currently mostly smartphones, tablets, and laptops.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).